Spread bets and CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 69% of retail investor accounts lose money when trading spread bets and CFDs with this provider. You should consider whether you understand how spread bets and CFDs work and whether you can afford to take the high risk of losing your money.
Open platformOpen platform

Sweden's SciBase Q3 net sales rise on higher electrode volumes

By Reuters News


Overview

  • Sweden medtech firm's Q3 net sales rose 41% yr/yr, driven by higher electrode volumes

  • Net loss widened in Q3, while loss per share improved due to higher share count

  • Gross margin improved to 72.3%, aided by production improvements despite currency and gold price impacts


Outlook

  • SciBase did not provide specific guidance for upcoming quarters or the full yr in the press release


Result Drivers

  • ELECTRODE SALES - Electrode sales volume increased by 36% and repeat sales to existing customers rose 40%

  • GEOGRAPHIC GROWTH - Sales in Germany skin cancer segment rose 18% vs Q2-25; US skin cancer sales up 68% and skin barrier segment up 286%

  • GROSS MARGIN FACTORS - Margin was negatively affected by currency and gold prices, and production ramp-up costs, but offset by production improvements


Company press release:


Key Details

Metric

Beat/Miss

Actual

Consensus Estimate

Q3 Sales

SEK 14.62 mln

Q3 Loss Per Share

SEK 2.52

Q3 Net Loss

SEK 25.77 mln

Q3 Gross Margin

72.30%


Analyst Coverage

  • Wall Street's median 12-month price target for SciBase Holding AB (publ) is SEK39.93, about 255% above its November 11 closing price of SEK11.25


Reuters Recommended Reads

  • Nov 12 - Germany's Stratec 9M sales fall, but cost cuts lift margins

  • Nov 12 - Medtech firm Ottobock Q3 revenue rises on B2B segment growth

  • Nov 10 - Switzerland's Alcon Q3 sales slightly miss estimates despite surgical equipment launches, vision care growth


For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.


(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)

Capital.com is an execution-only brokerage platform and the content provided on the Capital.com website is intended for informational purposes only and should not be regarded as an offer to sell or a solicitation of an offer to buy the products or securities to which it applies. No representation or warranty is given as to the accuracy or completeness of the information provided.
The information provided does not constitute investment advice nor take into account the individual financial circumstances or objectives of any investor. Any information that may be provided relating to past performance is not a reliable indicator of future results or performance.
To the extent permitted by law, in no event shall Capital.com (or any affiliate or employee) have any liability for any loss arising from the use of the information provided. Any person acting on the information does so entirely at their own risk.
 

Cryptocurrency-related content is intended solely as news and market commentary. Crypto Derivatives are not available to Retail clients registered with Capital Com (UK) Ltd.